TY  - JOUR

T1  - A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison.

JO  - Journal of Clinical Oncology

PY  - 2022/06/10

AU  - Jones RJ

AU  - Hussain SA

AU  - Birtle AJ

AU  - Song YP

AU  - Enting D

AU  - Faust G

AU  - Hilman S

AU  - Jagdev S

AU  - McGovern UB

AU  - Parikh O

AU  - Lewis A et al

ED  - 

DO  - DOI: 10.1200/jco.2022.40.17_suppl.lba4505

VL  - 40

IS  - 17_suppl

SP  - lba4505

EP  - lba4505

Y2  - 2024/12/21

ER  -